INVIVYD, INC. Operating Lease Liability
INVIVYD, INC. (IVVD) had Operating Lease Liability of $376.00 thousand as of 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-05-14
- 2026-03-31: Operating Lease, Liability $376.00K.
- 2025-12-31: Operating Lease, Liability $1.33M.
- 2025-03-31: Operating Lease, Liability $425.00K.
- 2024-12-31: Operating Lease, Liability $1.74M.
| Period end | Operating Lease, Liability | Operating Lease, Liability as first filed |
|---|---|---|
| 2026-03-31 | $376.00K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $1.33M 10-K · filed 2026-03-05 | |
| 2025-03-31 | $425.00K 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $1.74M 10-K · filed 2026-03-05 | |
| 2024-03-31 | $435.00K 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $1.73M 10-K · filed 2025-03-20 | |
| 2023-03-31 | $432.00K 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $837.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $1.51M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $2.86M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-11 | $1.66M 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |